ou can make a difference in the development of treatments and the advancement of gastric cancer research by sharing your patient or family experience. Join the Global Gastric Cancer Registry to help advance the understanding of what stomach (gastric) cancer is, how it affects individuals and families, the significance of genetics (CDH1, TP53, STK11, MSH2 or MLH1 gene mutations), Hereditary Diffuse Gastric Cancer (HDGC), Lynch Syndrome, Li-Fraumeni, Peutz-Jeghers, Emerging Germline Genetic Associations (CTNNA1, BRCA1/2, PALB2, RAD51C, ATM) and the role of genetics and biomarkers in targeted treatments and therapies.
We believe we can work together to fight stomach cancer by creating a research-ready community. Ready to engage in clinical trials, research and partnerships. By sharing our Gastric Cancer experiences, we can provide the data necessary to improve prevention, diagnosis and treatment of this deadly disease. Together, we can find a cure.
The Global Gastric Cancer Registry is founded by No Stomach For Cancer, an organization whose mission is to support research and unite the caring power of people worldwide affected by stomach cancer.
We hope that Gastric Cancer advocates around the world will support the registry. Together we can move closer to a world without stomach cancer. For more information, contact us at info@nostomachforcancer.org
Patients and families can now order the same genetic tests used by experts. Our easy-to-use, online experience offers guidance throughout the process from well-established, independent telemedicine providers.
This link is for informational purposes. PIN participants may access genetic testing through whichever lab and/or provider they feel most comfortable
ou can make a difference in the development of treatments and the advancement of gastric cancer research by sharing your patient or family experience. Join the Global Gastric Cancer Registry to help advance the understanding of what stomach (gastric) cancer is, how it affects individuals and families, the significance of genetics (CDH1, TP53, STK11, MSH2 or MLH1 gene mutations), Hereditary Diffuse Gastric Cancer (HDGC), Lynch Syndrome, Li-Fraumeni, Peutz-Jeghers, Emerging Germline Genetic Associations (CTNNA1, BRCA1/2, PALB2, RAD51C, ATM) and the role of genetics and biomarkers in targeted treatments and therapies.
Don't have an account? Register below.
SIGN UP